Since of cannabidiol neuroleptic impacts, CBD is capable to decrease the harshness of neurotic and/or obsessive behaviors in children, adults and even pets. Antipsychotic cannabidiol as well shown to efficiently reduce the symptoms of other chronic disorders such as schizophrenia, manic depression and bipolar disorder.

In US National Library of Medicine National Institutes of Health, and some US Universities we can read materials from several studies.

1. Cannabidiol as a Potential Treatment for Anxiety Disorders by Esther M. Blessing,  Maria M. Steenkamp, Jorge Manzanares, and Charles R. Marmar

Summary and Clinical Relevance

Evidence from human studies strongly supports the potential for CBD as a treatment for anxiety disorders: at oral doses ranging from 300 to 600 mg, CBD reduces experimentally induced anxiety in healthy controls, without affecting baseline anxiety levels, and reduces anxiety in patients with SAD. Limited results in healthy subjects also support the efficacy of CBD in acutely enhancing fear extinction, suggesting potential for the treatment of PTSD, or for enhancing cognitive behavioral therapy. Neuroimaging findings provide evidence of neurobiological targets that may underlie CBD’s anxiolytic effects, including reduced amygdala activation and altered medial prefrontal amygdala connectivity, although current findings are limited by small sample sizes, and a lack of independent replication. Further studies are also required to establish whether chronic, in addition to acute CBD dosing is anxiolytic in human. Also, clinical findings are currently limited to SAD, whereas preclinical evidence suggests CBD’s potential to treat multiple symptom domains relevant to GAD, PD, and, particularly, PTSD.

Conclusions

Preclinical evidence conclusively demonstrates CBD’s efficacy in reducing anxiety behaviors relevant to multiple disorders, including PTSD, GAD, PD, OCD, and SAD, with a notable lack of anxiogenic effects. CBD’s anxiolytic actions appear to depend upon CB1Rs and 5-HT1ARs in several brain regions; however, investigation of additional receptor actions may reveal further mechanisms. Human experimental findings support preclinical findings, and also suggest a lack of anxiogenic effects, minimal sedative effects, and an excellent safety profile. Current preclinical and human findings mostly involve acute CBD dosing in healthy subjects, so further studies are required to establish whether chronic dosing of CBD has similar effects in relevant clinical populations. Overall, this review emphasizes the potential value and need for further study of CBD in the treatment of anxiety disorders.

• Cannabidiol in Anxiety and Sleep: A Large Case Series by Scott Shannon, MD, Nicole Lewis, ND, Heather Lee, PA-C, and Shannon Hughes, PhD

Conclusion

Formal studies on efficacy and dose finding are much needed. Some urgency exists, given the explosion of lay interest in this topic and the rush to market these compounds. Current understanding of the physiology and neurologic pathways points to a benefit with anxiety-related issues. The results of our clinical report support the existing scientific evidence. In our study, we saw no evidence of a safety issue that would limit future studies. In this evaluation, CBD appears to be better tolerated than routine psychiatric medications. Furthermore, CBD displays promise as a tool for reducing anxiety in clinical populations, but given the open-label and nonrandomized nature of this large case series, all results must be interpreted very cautiously. Randomized and controlled trials are needed to provide definitive clinical guidance.

• Effects of Marijuana on Mental Health: Anxiety Disorders June 2017Effects of Marijuana on Mental Health:  Anxiety Disorders by Susan A. Stoner, PhD, Research Consultant University of Washington

In summary, effects of marijuana on anxiety disorders are complex. The endocannabinoid system appears to play an important role in responses to stress and anxiety. The two primary active ingredients of marijuana, THC and CBD, appear to have differing effects with regard to anxiety. Pure THC appears to decrease anxiety at lower doses and

Effects of Marijuana on Mental Health: Anxiety Disorders5  | P a g e  increase anxiety at higher doses. On the other hand, pure CBD appears to decrease anxiety at all doses that have been tested. There appears to be tolerance to these effects over a short period of time with regular use. There are individual differences in responses to marijuana that are affected by a variety of factors. Many people report using marijuana to cope with anxiety, and this may be particularly common among those with social anxiety disorder. Those who are concerned about marijuana increasing anxiety are unlikely to use it whereas those who use it and find it to be beneficial presumably continue to use marijuana. Doing so may offer some benefit in the short term, at least in terms of anxiety, but well-controlled studies indicate that use of marijuana is associated with increased likelihood of substance use disorders in the future.

• Investigation of the Therapeutic Potential of Cannabidiol (CBD) by José A. Crippa, Francisco S. Guimarães,  Alline C. Campos, and Antonio W. Zuardi

Conclusion

In conclusion, the experimental and clinical use of CBD, a compound that does not produce the typical subjective effects of marijuana induced by Δ9-THC, has clearly shown anxiolytic, antiepileptic, and antipsychotic properties, among other effects.

Since the 1970s, a number of scientific articles showing the potential therapeutic effects of CBD in different animal models of neuropsychiatric disorders and some clinical trials have been published. Recent investigations on the new effects of CBD and its synthetic analogs and on the comprehension of the mechanisms of action of this compounds as well as a better understanding of the endocannabinoid system have emerged.

However, new questions appeared regarding the properties of CBD and its synthetic analogs that are currently under investigation, such as the safety and precise dose ranges for each disorder. Therefore, more controlled clinical trials with different and larger neuropsychiatric populations should bring important answers in the near future and support the translation of research findings to clinical settings.